Posted February 14, 2012 by Bloomberg GlaxoSmithKline Plc (GSK) settled almost 25,000 cases over its Avandia diabetes drug in mediation as multidistrict litigation begins to wind down, lawyers told a judge today in Philadelphia. In November, U.S. District Judge Cynthia Rufe appointed a mediator to preside over settlement negotiations. She also set a 75-day deadline Full Article…
Search LawsuitInformation.org
Glaxo to Pay $3 Billion to Settle U.S. Sales, Avandia Cases
Posted November 4, 2011 by Bloomberg (Adds Avandia and Paxil settlements in 10th paragraph.) Nov. 3 (Bloomberg) — GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S. criminal and civil investigations into whether the U.K. company marketed drugs for unapproved uses and other matters, its biggest legal settlement. Negotiations over the terms will be Full Article…
GSK to pay $40.75 Million to 37 States
Posted June 24, 2011 on Domain-B GlaxoSmithKline Plc (GSK) and SB Pharmco Puerto Rico Inc yesterday agreed to pay $40.75 million to 37 US states and the District of Columbia to settle allegations on selling substandard antidepressants and other medicines produced at its former Puerto Rico factory in the early 2000′s. The 37 states had Full Article…
GSK Boss Gets $1.2Million Pay Cut After Poor Year
Posted March 2, 2011 on LSE LONDON, March 2 (Reuters) – GlaxoSmithKline Chief Executive Andrew Witty’s pay was cut by 734, 000 pounds ($1.2 million) to 2.3 million pounds last year after Britain’s biggest drugmaker missed its profit targets. The shortfall followed plunging sales of controversial diabetes pill Avandia, which was withdrawn from the market Full Article…
FDA Updates Info Guide on Avandia Side Effects
Posted February 10, 2011 on Seedol U.S. Food and Drug Administration (FDA) announced Thursday that updated information of Avandia side effects has been added to physician labeling and patient Medication Guide. The FDA, a federal agency of the United States, is responsible for protecting and promoting public health through the regulation and supervision of food Full Article…
Glaxo Suit on Avandia Heart Attack Death Settled on Trial’s Eve
Posted January 31, 2011 on Bloomberg GlaxoSmithKline Plc said it settled on the eve of trial a lawsuit alleging its Avandia diabetes drug caused a North Carolina man to die of a heart attack, avoiding a jury determination over risks associated with the medicine. The U.K.’s biggest drugmaker resolved the suit by the family of Full Article…
Glaxo’s Legal Problems Lead to New $3.4 Billion Charge
Posted January 17, 2011 on NY Times The British drug maker GlaxoSmithKline announced Monday that it was setting aside $3.4 billion — wiping out fourth-quarter profit — to pay for United States government investigations and product liability cases over its marketing of the diabetes drug Avandia. The one-time charge is expected to exceed GlaxoSmithKline’s quarterly Full Article…
Glaxo Linked Birth Defect of Fetus to Paxil, Ex-Executive Says
Posted September 18, 2010 on Bloomberg Sept. 18 (Bloomberg) — Officials of GlaxoSmithKline Plc, the U.K.’s largest drugmaker, said in 2001 that a birth defect in the fetus of a woman taking its Paxil antidepressant likely was linked to the drug, according to court testimony. After analyzing a 2001 e-mail from a Paxil user who Full Article…
And the Hits Just Keep Coming for Glaxo
Posted November 9, 2010 on Carey & Danis GlaxoSmithKline, the makers of the popular antidepressant Paxil, recently lost a civil lawsuit in Philadelphia. The jury in the case awarded $2.5 million to Michelle David, who had filed the lawsuit on behalf of her son, Lyam Kilker, who had just turned four. Michelle filed the suit Full Article…
Health Concerns Over Popular Contraceptives
Posted September 25, 2009 on NY Times The oral contraceptives Yaz and Yasmin are the top-selling pharmaceutical line for Bayer HealthCare, largely as a result of marketing that presents them as much more than mere pregnancy prevention. Yaz, in particular, the top-selling birth control pill in the United States, owes much of its popularity to Full Article…
